Protalix BioTherapeutics, Inc. (PLX)
PLXAMEXBiotechnology: Biological Products (No Diagnostic Substances)
$2.92
+0.3450 (+13.42%) today
Regular session, Nov 10, 2:11 PM ET
- Market cap
- $234.87m
- P/E
- 12.7
- EPS, last 4 quarters
- $0.2300
- Dividend yield
- –
- Day range
- $2.45 to $2.96
- 52-week range
- $1.65 to $3.19
- Average volume
- 152.5k
- Previous close
- $2.57
Analysts
1 coveringStrong Buy1 buy, 0 hold, 0 sell
Targets a year out average $12.00, +311.7% from here
Earnings
next estimate $-0.0200Next report
Sep 2025
-50.0%
Dec 2025
-800.0%
Mar 2026
+2300.0%
Jun 2026
+600.0%
estimate reported, and the surprise
Financials
| Quarter | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Revenue | $17.85m | $9.12m | $33.75m | $19.90m |
| Gross profit | $9.53m | $4.50m | $29.62m | $12.13m |
| Operating income | $2.13m | -$4.66m | $21.15m | $4.67m |
| Net income | $2.35m | -$5.50m | $18.32m | $3.78m |
Last four quarters: revenue $80.62m, margin 23.5%, free cash flow $7.67m
News
8 latest- Protalix Q3 Revenue Climbs; PRX-115 Topline Data Expected In H2 2027 RTTNews · 2 hours ago
- Protalix BioTherapeutics Inc. Q3 Income Advances RTTNews · 7 hours ago
- Protalix (PLX) Q2 2026 Earnings Call TranscriptThe Motley Fool · Aug 19, 2026
- Protalix Stock Down As FY25 Results Show Net Loss, Fabry Milestones Boosts Outlook RTTNews · Mar 18, 2026
- European Commission Approves J&J Prostate Drug, PLX Fabry Dosing, Incyte's Zynyz Second Indication RTTNews · Mar 13, 2026
- Protalix BioTherapeutics (PLX) Price Target Decreased by 12.00% to 11.22Fintel · Feb 4, 2026
- Protalix, Secarna Partner To Develop ASO Treatments For Rare Renal Conditions RTTNews · Dec 17, 2025
- Protalix BioTherapeutics (PLX) Price Target Decreased by 10.71% to 12.75Fintel · Dec 5, 2025
The company
Protalix is a biopharmaceutical company focused on the discovery, development, production, and commercialization of innovative therapeutics for rare diseases. Protalix has researched, developed, and currently manufactures two enzyme replacement therapies that are currently available in multiple markets. These therapies are recombinant therapeutic proteins expressed through Protalix's proprietary plant cell-based expression system, ProCellEx. ProCellEx is a unique plant cell-based system that enables Protalix to produce recombinant proteins in an industrial-scale manner with no exposure to mammalian cells. Protalix is the first company to gain U.S. Food and Drug Administration (FDA) approval of a protein produced through plant cell-based in suspension expression system. Protalix has licensed to Pfizer Inc. the worldwide development and commercialization rights to taliglucerase alfa, Elelyso, for the treatment of Gaucher disease, excluding in Brazil where Protalix retains full rights.
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- AMEX
- Region
- Middle East
- Website
- protalix.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.